journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/29140834/prognostic-factors-in-patients-with-metastatic-spinal-cord-compression-secondary-to-melanoma-a-systematic-review
#1
Nicholas J Hadden, Jerome R D McIntosh, Samuel Jay, Paula J Whittaker
Melanoma is one of the most common primary tumours associated with metastatic spinal cord compression (MSCC). The aim of this review is to identify prognostic factors specifically for MSCC secondary to melanoma. A systematic search of literature was performed in MEDLINE, Embase and the Cochrane Library to identify studies reporting prognostic factors for patients with MSCC secondary to melanoma. Two studies, involving a total of 39 patients, fulfilled the inclusion criteria. The variables associated with increased survival were receiving postoperative radiotherapy, receiving chemotherapy, perioperative lactate dehydrogenase level less than or equal to 8...
November 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29140833/immune-checkpoint-inhibitor-therapy-in-a-liver-transplant-recipient-with-a-rare-subtype-of-melanoma-a-case-report-and-literature-review
#2
James C Kuo, Leslie B Lilly, David Hogg
Immunotherapy with immune checkpoint inhibitors (ICIs) may be considered as a treatment option for various types of tumors, but the transplant recipient population as well as patients requiring long-term systemic immunosuppression for other reasons have been systematically excluded from clinical trials involving ICIs. We report a case of successful treatment with ICI in a liver transplant recipient diagnosed with a rare subtype of melanoma. This patient had not required any modification to her antirejection immunosuppression before or during immunotherapy, had not experienced any serious immune-related adverse event, and had a durable objective response for nearly 1...
November 14, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29135861/in-vitro-and-in-vivo-antimelanoma-effect-of-ethyl-ester-cyclohexyl-analog-of-ethylenediamine-dipropanoic-acid
#3
Andjelka M Isakovic, Sasa M Petricevic, Slavica M Ristic, Dusan M Popadic, Tamara K Kravic-Stevovic, Nevena S Zogovic, Jelena M Poljarevic, Tatjana V Zivanovic Radnic, Tibor J Sabo, Aleksandra J Isakovic, Ivanka D Markovic, Vladimir S Trajkovic, Sonja T Misirlic-Dencic
Melanoma, an aggressive skin tumor with high metastatic potential, is associated with high mortality and increasing morbidity. Multiple available chemotherapeutic and immunotherapeutic modalities failed to improve survival in advanced disease, and the search for new agents is ongoing. The aim of this study was to investigate antimelanoma effects of O,O-diethyl-(S,S)-ethylenediamine-N,N'di-2-(3-cyclohexyl) propanoate dihydrochloride (EE), a previously synthesized and characterized organic compound. Mouse melanoma B16 cell viability was assessed using acid phosphatase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, sulforhodamine B, and lactate dehydrogenase assays...
November 13, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29120964/analysis-of-survival-of-patients-treated-with-vemurafenib-ipilimumab-and-dabrafenib-for-advanced-skin-melanoma-in-daily-clinical-practice-real-world-data-retrospective-analysis-of-patients-treated-under-drug-reimbursement-programmes-in-poland-in-2013-2016
#4
Melania Brzozowska, Waldemar Wierzba, Andrzej Śliwczyński, Marcin Świerkowski, Piotr Potemski, Michał Marczak
Vemurafenib, ipilimumab and dabrafenib were registered for the treatment of advanced skin melanoma pursuant to the results of randomized phase III clinical trials. Real-world data on survival time for patients treated with those drugs in daily clinical practice are so far limited. Patients with advanced skin melanoma treated under reimbursement programmes (drug programmes), for which they were qualified pursuant to uniform inclusion criteria in force in all oncology centres in Poland. Data were obtained from the electronic databases of the national payer (NFZ) responsible for the implementation and monitoring of reimbursement (drug) programmes...
November 8, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076925/circulating-epithelial-tumor-cells-as-a-prognostic-tool-for-malignant-melanoma
#5
Katharina Pachmann, Regina Willecke-Hochmuth, Katrin Schneider, Martin Kaatz
Although immune therapies with checkpoint inhibitors have gained increasing attention in advanced and metastatic melanoma, interferon-α remains a standard therapy for nonmetastatic malignant melanoma with risk factors. Interferons can successfully prevent relapse; however, the response rate is still not as high as would be desired. Prognostic tools to predict the response are required, which could lead to more individualized treatment regimens. In numerous studies over the past decade, circulating epithelial tumor cells (CETCs) have been shown to be a promising biomarker for estimating the risk of metastatic relapse, and we sought to determine whether they can also be used for this purpose in malignant melanoma...
October 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076924/overexpression-of-mrna-decapping-enzyme-1a-predicts-disease-specific-survival-in-malignant-melanoma
#6
Yong Tang, Chao Xie, Yu Zhang, You Qin, Weikang Zhang
Our previous study identified that rs11551405 A allele located at the 3' UTR of mRNA-decapping enzyme 1a (DCP1A) was associated with an increased risk for malignant melanoma (MM). The aim of this study was to investigate whether that association is manifested at the DCP1A expression and whether an altered DCP1A expression can predict disease-specific survival (DSS) of MM patients. The DCP1A expression in specimens of 56 cases of primary MM (23 cases at TNM stage I-II and 33 cases at TNM stage III-IV) and 43 cases of benign nevi (BN) was measured by quantitative RT-PCR (qRT-PCR), immunohistochemistry, and western blotting...
October 25, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29023264/survival-trends-among-patients-with-metastatic-melanoma-in-the-pretargeted-and-the-post-targeted-era-a-us-population-based-study
#7
Dipesh Uprety, Amir Bista, Adithya Chennamadhavuni, Abesh Niroula, Syed Imran Mustafa Jafri, Angela Smith, Lubina Arjyal
In 2011, ipilimumab was approved by the US Food and Drug Administration (FDA) for metastatic melanoma. Since its approval, numerous targeted therapies have been approved by the FDA. Population-based studies assessing the survival benefit from these agents are lacking. We therefore carried out this study to compare the 1-year, 2-year, and median overall survival (OS) among metastatic melanoma patients in pretargeted and post-targeted eras. This is a retrospective study that utilized the Surveillance, Epidemiology, and End Results (SEER-18) database, version 8...
October 11, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076952/multiple-primary-melanoma-a-single-centre-retrospective-review
#8
Stephanie Menzies, Rupert Barry, Patrick Ormond
Prognosis has been shown to be worse for patients with multiple primary melanomas than those with a single melanoma. One recent retrospective study showed that older, white men were at higher risk of multiple primary melanomas. In our institution 2057 melanomas were diagnosed between January 1994 and March 2016. We identified 99 (4.8%) patients who had multiple primary melanomas. The average number of melanomas was 2.5 (range: 2-10). The site for first and second melanomas was similar in 30%. We found that subsequent melanomas were more likely to be in situ and thinner in terms of Breslow thickness and Clarks level...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076951/cisplatin-dacarbazine-and-vinblastine-as-first-line-chemotherapy-for-liver-metastatic-uveal-melanoma-in-the-era-of-immunotherapy-a-single-institution-phase-ii-study
#9
Giovanni Schinzari, Ernesto Rossi, Alessandra Cassano, Vincenzo Dadduzio, Michela Quirino, Monica Pagliara, Maria A Blasi, Carlo Barone
No standard therapy is established for metastatic uveal melanoma. Liver involvement in uveal melanoma may lead to organ impairment, which represents a common cause of death. Tumor shrinkage might improve survival by delaying hepatic failure. Since the combination of cisplatin, vinblastine, dacarbazine allowed a high response rate in metastatic cutaneous melanoma, we explored efficacy and safety of this regimen in unresectable liver metastases of uveal melanoma. In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076950/vemurafenib-treatment-for-patients-with-locally-advanced-unresectable-stage-iiic-or-metastatic-melanoma-and-activating-exon-15-braf-mutations-other-than-v600e
#10
Sigrun Hallmeyer, Rene Gonzalez, David H Lawson, Lee D Cranmer, Gerald P Linette, Igor Puzanov, Bret Taback, C Lance Cowey, Antoni Ribas, Gregory A Daniels, Timothy Moore, Geoffrey T Gibney, Hussein Tawbi, Eric Whitman, Geraldine Lee, Yong Mun, Shiyao Liu, Omid Hamid
BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutations other than V600E are reported. Eligible patients with stage IIIC or IV melanoma and non-V600E BRAF mutations received vemurafenib (960 mg, twice daily). End points included investigator-assessed best overall response rate (primary), time to response, duration of response, progression-free survival, overall survival and safety...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29076949/resistance-mechanisms-to-genetic-suppression-of-mutant-nras-in-melanoma
#11
James P Robinson, Vito W Rebecca, David A Kircher, Mark R Silvis, Inna Smalley, Geoffrey T Gibney, Kristin J Lastwika, Guo Chen, Michael A Davies, Douglas Grossman, Keiran S M Smalley, Sheri L Holmen, Matthew W VanBrocklin
Targeted therapies have revolutionized cancer care, but the development of resistance remains a challenge in the clinic. To identify rational targets for combination strategies, we used an established melanoma mouse model and selected for resistant tumors following genetic suppression of NRAS expression. Complete tumor regression was observed in all mice, but 40% of tumors recurred. Analysis of resistant tumors showed that the most common mechanism of resistance was overexpression and activation of receptor tyrosine kinases (RTKs)...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29036015/transient-pituitary-acth-dependent-cushing-syndrome-caused-by-an-immune-checkpoint-inhibitor-combination
#12
Jeremy Lupu, Cécile Pages, Pauline Laly, Julie Delyon, Marie Laloi, Antoine Petit, Nicole Basset-Seguin, Imen Oueslati, Anne-Marie Zagdanski, Jacques Young, Clara Bouche, Céleste Lebbé, Jean-François Gautier
Immune checkpoint inhibitors have improved survival in numerous advanced malignancies, but are associated with a number of immune-related adverse events, including endocrinopathies. Endogenous Cushing's syndrome (CS) is a rare disorder resulting from exposure to high levels of circulating cortisol. CS can be caused either by adrenal cortex tumors or hyperplasia or by pituitary or extra-pituitary tumors over-secreting ACTH (known as ACTH-dependent CS). We report the first case of transient ACTH-dependent CS, which appeared after combined ipilimumab and nivolumab therapy...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29036014/a-family-with-two-cases-of-melanocytic-tumors-and-fragile-x-syndrome
#13
Candice Lesage, Isabelle Coupier, Bernard Guillot
Fragile X syndrome (FXS), a leading cause of inherited intellectual disability, most commonly results from an expansion of the CGG trinucleotide repeat in the fragile X mental retardation 1 (FMR1) gene to more than 200 copies (full mutation). The FXS phenotype differs by sex and is associated with intellectual and cognitive impairment, characteristic physical features, epilepsy, and/or behavioral challenges including autism spectrum disorder. In this patient population, tumors involving blood cells, digestive organs, the central nervous system, and testes have been described, but melanocytic tumors have not been reported...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29016387/lymphocyte-to-monocyte-ratio-is-associated-with-survival-in-pembrolizumab-treated-metastatic-melanoma-patients
#14
Jarrett J Failing, Yiyi Yan, Luis F Porrata, Svetomir N Markovic
The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/29016386/primary-malignant-melanoma-arising-in-an-ovarian-cystic-teratoma
#15
Xuejie Shen, Yang Fan, Shui Cao
Primary malignant melanoma arising in an ovarian cystic teratoma is exceedingly rare event with an estimated incidence of 0.2-0.8%. So far, there have been approximately only 47 relevant reports. We report a case of primary malignant melanoma of the ovary arising in a cystic teratoma here. Moreover, we review systematically the disease from the following aspects, that origin, clinical characteristics, accessory examination, pathological features, diagnosis, differential diagnosis, treatment, prognosis.
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28984691/intracorneal-pustular-drug-eruption-a-novel-cutaneous-adverse-event-in-anti-programmed-cell-death-1-patients-that-highlights-the-effect-of-anti-programmed-cell-death-1-in-neutrophils
#16
Cathy Yunjia Zhao, Germana Consuegra, Shaun Chou, Pablo Fernández-Peñas
The introduction of anti-programmed cell death-1 (anti-PD1) monoclonal antibodies has revolutionized the treatment of various advanced malignancies. Despite its efficacy, anti-PD1 therapy is accompanied by a variety of cutaneous adverse events. A 79-year-old man developed erythematous scaly plaques and pustules of the forehead, legs and arms after four cycles of nivolumab infusions every 2 weeks. Histology showed intracorneal pustules with dermal neutrophils and eosinophils. He was treated successfully with topical corticosteroids without discontinuation of nivolumab...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28984690/pd-1-pd-l1-and-vegf-a-vegf-c-expression-in-lymph-node-microenvironment-and-association-with-melanoma-metastasis-and-survival
#17
Cristina Alessi, Cristovam Scapulatempo Neto, Cristiano R Viana, Vinicius de Lima Vazquez
Regional lymph nodes are affected frequently by melanoma metastasis. Its microenvironment may be associated with tumor progression. We investigated sentinel nodes with and without tumor and negative nodes surrounding positive nodes, looking for patterns related to tumor immune interaction and lymphovascular progression. We quantified programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1, vascular endothelial growth factor (VEGF)-A/VEGF-C expressions in lymph nodes of 103 patients who underwent sentinel lymph node biopsy...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28885396/a-prospective-multicenter-cohort-study-of-cutaneous-melanoma-clinical-staging-and-potential-associations-with-hif-1%C3%AE-and-vegf-expressions
#18
Miguel Ángel Martínez-García, Erica Riveiro-Falkenbach, José L Rodríguez-Peralto, Eduardo Nagore, Antonio Martorell-Calatayud, Francisco Campos-Rodríguez, Ramón Farré, Luis Hernández Blasco, Jose Bañuls Roca, Eusebi Chiner Vives, Alicia Sánchez-de-la-Torre, Jorge Abad Capa, Josep Maria Montserrat, Isaac Almendros, Amalia Pérez-Gil, Valentin Cabriada Nuño, Irene Cano-Pumarega, Jaime Corral Peñafiel, Trinidad Diaz Cambriles, Olga Mediano, Joan Dalmau Arias, David Gozal
Melanoma is a highly prevalent cancer that is associated with substantial mortality. Although clinical staging procedures can serve as relatively robust prognostic indicators, we aimed to determine whether assessments of the abundance of hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor (VEGF) in postexcisional melanoma tumor tissues may enable more accurate determination of tumor aggressiveness. We carried out a multicenter prospective study, in which we systematically evaluated 376 consecutive patients diagnosed with melanoma, and performed histochemical assessments for both HIF-1α and VEGF immunoreactivity in the tumor biopsies...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28877050/metformin-oxidative-and-proliferative-parameters-in-vitro-and-in-vivo-models-of-murine-melanoma
#19
Fernando P de Souza Neto, Sara S Bernardes, Poliana C Marinello, Gabriella P Melo, Rodrigo C Luiz, Rubens Cecchini, Alessandra L Cecchini
Cutaneous melanoma is one of the most lethal cancers because of its increased rate of metastasis and resistance to available therapeutic options. Early studies indicate that metformin has beneficial effects on some types of cancer, including melanoma. To clarify knowledge of the mechanism of action of metformin on this disease, two treatment-based approaches are presented using metformin on melanoma progression: an in-vitro and an in-vivo model. The in-vitro assay was performed for two experimental treatment periods (24 and 48 h) at different metformin concentrations...
December 2017: Melanoma Research
https://www.readbyqxmd.com/read/28872489/a-case-of-pure-red-cell-aplasia-during-nivolumab-therapy-for-cardiac-metastatic-melanoma
#20
Akihiko Yuki, Tatsuya Takenouchi, Sumiko Takatsuka, Takuro Ishiguro
Nivolumab is an antibody against programmed cell death 1 and functions as an immune checkpoint inhibitor for various malignancies, including unresectable melanomas. Nivolumab causes several immune-related adverse events, which typically include skin rash, pneumonitis, thyroid dysfunction, hepatitis, and colitis; in rare cases, anemia may be present. There are several reports of autoimmune hemolytic anemia that has developed in response to nivolumab; however, there are few reports of pure red cell aplasia (PRCA)...
December 2017: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"